Bone marrow transplants from peripheral blood
نویسندگان
چکیده
منابع مشابه
Bone marrow transplants.
In order to investigate the applicability of techniques to assess the costs and benefits of medical technology, 19 case studies were prepared. All 19 are available individually. In addition, 17 of the cases are available in a collected volume, Background Paper #2: Case Studies of Medical Technologies. Some of the cases represent formal cost-effectiveness analysis (e.g., the case on bone marrow ...
متن کاملAutologous bone marrow transplants.
rights reserved. retrieval systems, without prior written permission from the Publisher. All electronic or mechanical, including photocopying or by information storage or may be reproduced, displayed, or transmitted in any form or by any means, United States copyright law (Title 17, U.S. Code), no part of by Project HOPE The People-to-People Health Foundation. As provided by Road, Suite 600, Be...
متن کاملGranulocyte / Macrophage Progenitor Cells From Peripheral Blood and Bone Marrow
Prostaglandins of the E series (PGE) inhibit proliferation of normal bone marrow granulocyte/macrophage progenitors (CFU-GM). Circulating CFU-GM are known to differ from marrow CFU-GM in many characteristics, and in the present study, we compared the effect of PGE1 on circulating and bone marrow progenitors in normals and in patients with chronic myelogenous leukemia (CML). PGE, caused a dose-d...
متن کاملPeripheral-blood stem cells versus bone marrow from unrelated donors.
BACKGROUND Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased ra...
متن کاملPeripheral blood stem cell transplants.
Autologous peripheral blood stem cell transplantation High dose myeloablative treatment followed by autologous haemopoietic stem cell rescue is increasingly used in the treatment of haematological malignancies and solid tumours with the aim of achieving a dose–response eVect. Apart from the risk of disease relapse, the major drawback of this approach is the risk of procedure related toxicity re...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1994
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.309.6946.4